@article{Cheetham_N-2023_109592,
title = {Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors},
author = {Cheetham, N. and Kibble, M. and Wong, A. and Silverwood, R. and Knuppel, A. and Williams, D. and Hamilton, O. and Lee, P. and Bridger Staatz, C. and Di Gessa, G. and Zhu, J. and Katikireddi, S. and Ploubidis, G. and Thompson, E. and Bowyer, R. and Zhang, X. and Abbasian, G. and Garcia, M. and Hart, D. and Seow, J. and Graham, C. and Kouphou, N. and Acors, S. and Malim, M. and Mitchell, R. and Northstone, K. and Major-Smith, D. and Matthews, S. and Breeze, T. and Crawford, M. and Molloy, L. and Kwong, A. and Doores, K. and Chaturvedi, N. and Duncan, E. and Timpson, N. and Steves, C.},
month = {jan},
year = {2023},
abstract = {Background:SARS-CoV-2 antibody levels can be used to assess humoral immune responses following SARS-CoV-2 infection or vaccination, and may predict risk of future infection. Higher levels of SARS-CoV-2 anti-Spike antibodies are known to be associated with increased protection against future SARS-CoV-2 infection. However, variation in antibody levels and risk factors for lower antibody levels following each round of SARS-CoV-2 vaccination have not been explored across a wide range of socio-demographic, SARS-CoV-2 infection and vaccination, and health factors within population-based cohorts.},
journal = {eLife},
publisher = {eLife Sciences Publications},
url = {https://doi.org/10.7554/eLife.80428},
}
